EMRIS Pharma

EMRIS PharmaEMRIS Pharma
EMRIS Pharma

EMRIS Pharma

Developing topical treatments to prevent and treat skin toxicities from cancer therapies.

Website
DR 102021Active7Tel Aviv, Israel
Rate
Advertise here

About

EMRIS Pharma is developing a first-in-class topical solution to prevent skin toxicities associated with targeted cancer therapies, particularly EGFR inhibitors. Their innovation aims to improve patients' quality of life and treatment compliance by blocking anti-cancer drugs in the skin without interfering with the therapy. This addresses the significant unmet need of severe skin side effects experienced by 80%-90% of patients treated with these drugs.
Frequently asked

What does EMRIS Pharma do?

EMRIS Pharma is developing a first-in-class topical solution to prevent skin toxicities associated with targeted cancer therapies, particularly EGFR inhibitors. Their innovation aims to improve patients' quality of life and treatment compliance by blocking anti-cancer drugs in the skin without interfering with the therapy. This addresses the significant unmet need of severe skin side effects experienced by 80%-90% of patients treated with these drugs.

What is EMRIS Pharma's revenue?

StartupHub estimates EMRIS Pharma's annual revenue at $1.2M (range $667K to $1.9M, 64% confidence), based on comparable companies in the sector.

Where is EMRIS Pharma headquartered?

EMRIS Pharma is headquartered in Tel Aviv, Israel.

When was EMRIS Pharma founded?

EMRIS Pharma was founded in 2021.

What industry does EMRIS Pharma operate in?

EMRIS Pharma operates in Life Sciences, Oncology, Biotech, MedTech, HealthTech, Drug Discovery.

How many employees does EMRIS Pharma have?

EMRIS Pharma has approximately 7 people on record.

HEADCOUNT
7
DOMAIN RATING
10
Comments

No comments yet. Be the first to share your take.